FDA Calls for End to Priority Review Vouchers as GAO Says Too Early to Gauge Effectiveness
The US Government Accountability Office (GAO) said in March 2016 within a new report that it’s still too early to assess whether the Food and Drug Administration’s (FDA) three-year-old pediatric priority review voucher (PRV) program has stimulated the development of drugs to treat or prevent rare pediatric diseases.